This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SCIO-469

Johnson & Johnson

Drug Names(s): SCIO 469

Description: SCIO-469 inhibits p38 MAP kinase, a stimulatory modulator of pro-inflammatory factors including tumor necrosis factor-alpha (TNF-alpha), IL-1, and cyclooxygenase-2 (COX-2), all of which are known to contribute to both symptoms and disease progression in patients with RA. Preclinical data demonstrated that oral SCIO-469 leads to suppression of induced TNF-alpha levels over a wide range of doses.

Existing protein-based products that antagonize TNF-alpha are prescription products administered only through injection or infusion, and they represent a multi-billion dollar annual market in the United States. If approved, SCIO-469 would be one of the first mechanism-specific oral products aimed at reducing TNF-alpha.

Deal Structure: SCIO-469 is developed by Scios, a member of the Johnson & Johnson Family of Companies.


SCIO-469 News

Pink Sheet Scios merger talks


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug